Heating evaporation device and chemical evaporation method

Abstract

To provide a heat-transpiration device that allows heat-transpiration of an agent in a short time and also allows the use of a battery as a power supply and is suitable for outdoor use.SOLUTION: A heat-transpiration device 1 has a carrier 5 containing an agent, a heating element 4 that heats the carrier 5, and a battery 3 that supplies the heating element 4 with power. Until five to sixty seconds have elapsed from the start of power supply to the heating element 4, heat radiation from the heating element 4 causes the surface of the carrier 5 to be heated to a temperature from 200°C to 500°C, thereby transpiring the agent. Thus, the heat-transpiration device can be easily carried indoors and is also suitable for outdoor use.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] The present invention relates to a heating evaporation device and a chemical evaporation method. [Background technology]

[0002] Conventionally, for the purpose of pest control and the like, thermal evaporation devices have been proposed that include a carrier containing a chemical agent and a heating element that heats the carrier (see, for example, Patent Document 1). For example, in conventional thermal evaporation devices (hereinafter referred to as "conventional devices"), in order to evaporate the chemical agent by heat, an electric heating means is used to heat the heating element, and the heated heating element heats the carrier. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] Japanese Patent Application Publication No. 9-74971 Summary of the Invention [Problem to be solved by the invention]

[0004] Generally, conventional devices heated by an electric heating means continuously heat the heating element to evaporate the chemicals over a long period of time. Such conventional devices are designed to be connected to an AC power source of 100V to 200V, the same as the power source used in ordinary Japanese homes, and to be used continuously for a long period of time. In other words, using conventional devices inevitably consumes a large amount of power (voltage (V) x current (A) x time (h)). In addition, conventional devices require a long time to heat and evaporate the chemicals. For this reason, conventional devices are designed for indoor use, and simply taking them outdoors makes it difficult for them to function as designed (i.e., to effectively evaporate the chemicals).

[0005] For example, even if you forcibly take it outdoors and connect it to a battery, the power that can be output from the battery is generally much smaller than that of a household power source, and there is also a limit to the length of time that it can be used continuously. Therefore, even if you use conventional devices outdoors, it is difficult for them to operate as designed, and they are not suitable for outdoor use. Furthermore, conventional devices could not be used indoors unless there was an electrical outlet, such as in the entrance, hallway, or closet.

[0006] The present invention has been made in consideration of the above-mentioned circumstances, and its purpose is to provide a heating evaporation device that can heat and evaporate chemicals in a short period of time, can use a battery as a power source, and is suitable for outdoor use, as well as a method of evaporating chemicals using the heating evaporation device. [Means for solving the problem]

[0007] The above object of the present invention can be achieved by the following configuration. [1] A heating and evaporation device comprising: a carrier containing a drug; a heating element for heating the carrier; and a battery for supplying power to the heating element, The heating element is The battery generates heat when power is supplied from the battery, The resistance value when the heat is stable is within the range of 0.7Ω to 5.0Ω. The heating and evaporation device comprises: The surface temperature of the carrier is heated to a range of 200°C to 500°C by heat radiation from the heating element within 5 to 60 seconds from the start of energization of the heating element, thereby evaporating the drug. Heating evaporation device. [2] A chemical vaporization method using a heating vaporization device, The heating and evaporation device is The device comprises a carrier containing a drug, a heating element for heating the carrier, and a battery for supplying power to the heating element, The heating element is The battery generates heat when power is supplied from the battery, The resistance value when the heat is stable is within the range of 0.7Ω to 5.0Ω. The drug evaporation method comprises: The method includes a step of heating the surface temperature of the carrier to a range of 200°C to 500°C by heat radiation from the heating element within 5 to 60 seconds from the start of energizing the heating element, thereby evaporating the drug. Drug evaporation method.

[0008] The thermal evaporation device of the configuration [1] above is configured to heat the surface temperature of the carrier to a temperature range of 200°C to 500°C by heat radiation from the heating element within 5 to 60 seconds after the start of power supply to the heating element, even though it uses a battery which is usually much lower voltage than a household power source of 100V to 200V.

[0009] Specifically, the resistance of the heating element is 0.7Ω to 5.0Ω, which is extremely low compared to the resistance of conventional heating elements, which is 1kΩ to 10kΩ. Because the resistance (R) of the heating element is lower than conventional elements, the value of the current (I) flowing through the heating element is larger even if the voltage (V) of the power supply connected to the heating element is the same. As a result, even if the current application time (t) is short, a sufficient amount of Joule heat (Q = V 2 / R×t) can be released from the heating element. In other words, the heating element heats up faster than before.

[0010] Specifically, the resistance value of the heating element is preferably in the range of 0.7Ω to 5.0Ω, more preferably in the range of 0.8Ω to 4.0Ω, and most preferably in the range of 1.0Ω to 3.0Ω.

[0011] In addition, conventional devices generally use PTC (positive temperature coefficient thermistor) as the heating element. When a PTC generates heat, its resistance increases and the heating power P (P = V 2 For this reason, when PTC is used in a thermal evaporation device, it is difficult to reach temperatures of 200°C to 500°C.

[0012] Therefore, the heating element of the present invention is preferably a constant resistance such as a nichrome wire, which has a constant resistance regardless of temperature. It is also possible to use an NTC (negative temperature coefficient) thermistor, which has a resistance that decreases as the temperature increases.

[0013] Regarding the evaporation of the drug, the inventors have found that if the surface temperature of the carrier is heated to 200°C to 500°C, the drug can be sufficiently evaporated even if the device is operated for a short period of time, such as 5 to 60 seconds. To achieve this, as described above, the heating element of the thermal evaporation device of this configuration has a resistance value of 0.7Ω to 5.0Ω, which increases the temperature rise rate of the heating element, and the surface temperature of the carrier can be heated to a temperature range of 200°C to 500°C by heat radiation from the heating element within 5 to 60 seconds after the start of current application, thereby allowing the drug to be sufficiently evaporated.

[0014] Specifically, the heating time is preferably 5 to 60 seconds, more preferably 7 to 50 seconds, and most preferably 10 to 40 seconds. The surface temperature is more preferably 270 to 380°C.

[0015] In addition, batteries generally have a fixed capacity, and it is desirable that the amount of power consumed be small when the battery is used within a range in which the target temperature can be obtained, i.e., the amount of power consumed be reduced. The heating and evaporation device of this configuration has a short power-on time (t), thereby reducing the amount of power consumed (voltage (V) x current (A) x time (h)). Specifically, the heating and evaporation device of this configuration can reduce the amount of heat loss by shortening the power-on time until the target temperature is reached. Therefore, the heating and evaporation device of this configuration can prevent unnecessary power consumption at startup, such as eliminating the need to power on the device well in advance of the time of use, and the operating time is also shortened, thereby reducing the amount of power consumed. In other words, the heating and evaporation device of this configuration has a structure that is also preferable when using a battery. Therefore, the heating and evaporation device of this configuration is suitable for both outdoor use and indoor portability in terms of the amount of power consumed (i.e., battery capacity).

[0016] The thermal evaporation device of this configuration can use primary or secondary (rechargeable) batteries. Primary batteries include manganese batteries, alkaline batteries, silver oxide (SR) button batteries, alkaline (LR) button batteries, and coin-type lithium batteries (CR). Secondary batteries include nickel-cadmium batteries, nickel-metal hydride batteries, lithium-ion batteries, and lithium polymer batteries, but lithium-ion batteries and lithium polymer batteries are preferred in terms of electromotive force and battery capacity.

[0017] In addition, when using a rechargeable battery, the battery can be charged using a USB power source. Note that since the present invention is a heating evaporation device that uses a battery as its power source, it is also possible to use a USB power source, which has more power than a battery, as the power source.

[0018] The chemical vaporization method of the configuration [2] above uses a battery, which typically has a much lower voltage than a 100V to 200V household power source. However, within 5 to 60 seconds after the start of current application to the heating element, the surface temperature of the carrier can be heated to a temperature range of 200°C to 500°C by electric heat from the heating element. Specifically, as described above, the resistance value of the heating element is 0.7Ω to 5.0Ω, which increases the heating element's temperature rise rate. Within 5 to 60 seconds after the start of current application, the heat dissipated from the heating element heats the surface temperature of the carrier to a predetermined temperature range (200°C to 500°C), allowing for sufficient chemical vaporization. Therefore, the thermal vaporization device of this configuration is suitable for both outdoor use and indoor portability.

[0019] Furthermore, the thermal evaporation device of this configuration has a fast temperature rise rate, which shortens the operating time and reduces the amount of power consumed. In other words, the thermal evaporation device of this configuration has a structure that is also preferable when using a battery. Therefore, the thermal evaporation device of this configuration is suitable for both outdoor use and indoor portability, from the perspective of the amount of power consumed, i.e., the battery capacity. [Effects of the Invention]

[0020] The thermal evaporation device of the present invention can heat and evaporate a drug in a short period of time, and can also use a battery as a power source, making it suitable for outdoor use.It is also possible to provide a thermal evaporation device and a method for evaporating a drug using the thermal evaporation device.

[0021] The present invention has been briefly described above. The details of the present invention will become more apparent from the detailed description of the invention set forth below, taken in conjunction with the accompanying drawings. [Brief explanation of the drawings]

[0022] [Figure 1] FIG. 1 is a schematic diagram of a thermal evaporation device according to an embodiment of the present invention. [Figure 2] FIG. 2 is a schematic diagram of a transpiration test using the heating transpiration device of the present invention. [Figure 3] FIG. 3 is a schematic (perspective) view of the heating element and carrier in FIG. [Figure 4] FIG. 4 is a graph showing the relationship between "surface temperature" and "transpiration rate" in Test 1. [Figure 5] FIG. 5 is a schematic diagram showing the evaluation test in Test 4. DETAILED DESCRIPTION OF THE INVENTION

[0023] <Embodiment> Hereinafter, a thermal evaporation device 1 (hereinafter simply referred to as "thermal evaporation device 1") according to an embodiment of the present invention will be described with reference to the drawings. The thermal evaporation device 1 according to an embodiment of the present invention evaporates a drug by heating a carrier 5 containing the drug with a heating element 4, and is powered by a battery 3.

[0024] 1 is a schematic diagram showing an example of the configuration of a thermal evaporation device 1 according to this embodiment. The thermal evaporation device 1 has a housing 2, a battery 3, a heating element 4, a carrier 5, and a control unit 6. The housing 2 is formed with an opening (a so-called drug evaporation port) for discharging the drug that has been thermally evaporated to the outside of the housing 2.

[0025] In the thermal evaporation device 1, power is supplied to the heating element 4 by a battery 3. The control unit 6 constitutes a part of the housing 2 and is disposed in the housing 2. That is, the thermal evaporation device 1 can start (i.e., turn on) or stop (i.e., cut off) the power supply to the heating element 4 via the control unit 6. This allows the user of the thermal evaporation device 1 to turn on / off the device from outside the housing 2. For example, the control unit 6 includes a switch (not shown), and the user can turn on the device by pressing this switch once, and then turn off the device by pressing the switch again.

[0026] Inside the housing 2, a battery 3, a heating element 4, a carrier 5, and a control unit 6 are arranged. These are connected in series to form a closed circuit through which current circulates. A carrier 5 containing a drug is placed on the heating element 4. The heating element 4 is electrically connected to the battery, which serves as a power supply, via a switch. The heating element 4 is configured to begin generating heat when power is supplied, and generates heat when power is applied. In other words, when a user presses the switch from outside the housing 2, power is supplied from the battery 3 to the heating element 4. Then, current flows through the heating element 4, generating Joule heat. The heating element 4 is a resistance heater that generates heat through this Joule heat. In this way, heat is transferred from the generated heating element 4 to the carrier 5, and the carrier 5 is heated (so-called indirect resistance heating).

[0027] The carrier 5 is heated to a surface temperature in the range of 200°C to 500°C within 5 to 60 seconds after the start of current flow from the battery 3 to the heating element 4, and the drug evaporates. In this way, the heating element 4 functions as a heating means for heating the carrier 5 and evaporating the drug from the carrier 5. The heating element 4 is arranged so that multiple or at least one heat-resistant material such as a mica plate, a metal plate, or a glass plate is sandwiched between the carrier 5 and the heating element 4 to prevent contamination of the heating element 4.

[0028] Next, the heating element 4 will be described. As shown in FIG. 3, the heating element 4 has both ends (upper left and lower right) formed into approximately rectangular portions, and the center is formed into a spiral shape. A power source or the like is connected to each of the approximately rectangular portions at both ends. Note that, although the heating element 4 is configured as described above in this embodiment, the shape is not limited to this. In other words, the shape of the heating element 4 can be freely selected from rectangular, circular, coil-like, strip-like, etc.

[0029] The resistance value of the heating element 4 is 0.7Ω to 5.0Ω, which is extremely low compared to the resistance of conventional heating elements, which is 1kΩ to 10kΩ. Because the resistance value (R) of the heating element 4 is lower than conventional heating elements, the value of the current (I) flowing through the heating element 4 is larger even if the voltage (V) of the power supply connected to the heating element 4 is the same. As a result, even if the current application time (t) is short, a sufficient amount of Joule heat (Q=V 2 / R×t) can be released from the heating element 4. That is, the time required for the heating element 4 to heat up becomes shorter than before.

[0030] That is, as described above, in the thermal evaporation device 1, the resistance value of the heating element 4 is 0.7Ω to 5.0Ω, and the heating element 4 has a short temperature rise time, so that the surface temperature of the carrier 5 can be heated to a temperature range of 200°C to 500°C by heat radiation from the heating element 4 within 5 to 60 seconds after the start of current application, which is unprecedented for battery-powered devices, and the drug can be sufficiently evaporated. Therefore, the thermal evaporation device 1 can heat and evaporate the drug in a short time, and can also use a battery as a power supply, making it portable and suitable for outdoor use.

[0031] Next, the agent will be described. In this embodiment, for example, when the purpose is pest control, the agent preferably has a pest control component. The pest control component is a component that can kill, repel, knock down, or the like, target pests. The type of pest control component is not particularly limited, and known compounds can be used.

[0032] Examples of pest control ingredients include transfluthrin, cyphenothrin, permethrin, pyrethrins, allethrin, phthalthrin, resmethrin, furamethrin, fenothrin, empenthrin, prallethrin, imiprothrin, cyfluthrin, cypermethrin, deltamethrin, dimefluthrin, mepafluthrin, tralomethrin, profluthrin, and pyrethroid compounds such as metofluthrin and etofenprox; silicon compounds such as silafluofen; fenitrothion; and dichlorvos. , organophosphorus compounds such as chlorpyrifos methyl, diazinon, and fenthion, carbamate compounds such as carbaryl and propoxur, oxadiazole compounds such as methoprene, pyriproxyfen, fipronil, broflanilide, and amidoflumet, compounds such as peppermint oil, orange oil, fennel oil, cinnamon oil, clove oil, turpentine, eucalyptus oil, cypress oil, jasmine oil, neroli oil, peppermint oil, bergamot oil, butiglen oil, lemon oil, lemongrass Examples of essential oil components include laurel oil, cinnamon oil, citronella oil, geranium oil, lavender oil, patchouli oil, cypress oil, citral, l-menthol, citronellyl acetate, cinnamic aldehyde, terpineol, nonyl alcohol, cis-jasmone, limonene, linalool, 1,8-cineole, geraniol, α-pinene, p-menthane-3,8-diol, eugenol, menthyl acetate, thymol, benzyl benzoate, and benzyl salicylate; glycol ethers such as propylene glycol monopropyl ether, propylene glycol monobutyl ether, dipropylene glycol monopropyl ether, dipropylene glycol monobutyl ether, dipropylene glycol dimethyl ether, ethylene glycol monoisobutyl ether, diethylene glycol monoisobutyl ether, diethylene glycol dibutyl ether, diethylene glycol dimethyl ether, and triethylene glycol dimethyl ether; and dibasic acid esters such as dibutyl adipate. These may be used alone or in combination of two or more.

[0033] The pest control component may be appropriately selected depending on the type of target pest. Examples of target pests include mosquitoes, flies, moths, bees, stink bugs, cockroaches, ants, spiders, pill bugs, mites, lice, centipedes, caterpillars, millipedes, spiders, horseflies, black flies, moth flies, termites, midges, leafhoppers, bark beetles, ground beetles, earwigs, silverfish, longhorn beetles, dermestid beetles, booklice, bur moths, midges, and the like. For flying pests such as mosquitoes, flies, moths, bees, horseflies, black flies, moth flies, leafhoppers, moth flies, moth flies, and moth flies, transfluthrin, metofluthrin, mepafluthrin, profluthrin, phthalthrin, prallethrin, momfluorothrin, cyphenothrin, and the like are suitable. Furthermore, for crawling pests such as cockroaches, stink bugs, ants, spiders, pill bugs, mites, lice, centipedes, caterpillars, millipedes, spiders, termites, wood beetles, ground beetles, earwigs, silverfish, and the like, phthalthrin, prallethrin, imiprothrin, permethrin, fenothrin, and the like are suitable.

[0034] In addition to pest control components, the active ingredients that can be used in the present invention include fragrance components and disinfecting components.

[0035] Examples of fragrance components include lauric acid methacrylate, flavonoids, plant extracts such as green tea extract, geranyl crotonate, acetophenone myristate, anisic aldehyde, diphenyl oxide, methyl benzoate, ethyl benzoate, ethyl phenylacetate, safrole, sedum oil, sedum rapeseed oil, citronella oil, petitgrain oil, and lemongrass oil. Examples of natural fragrances include natural essential oils such as orange oil, lemon oil, lavender oil, lavandin oil, bergamot oil, patchouli oil, cedarwood oil, and peppermint oil. Examples of synthetic fragrances include hydrocarbon terpenes such as α-pinene, β-pinene, limonene, p-cymene, terpinolene, α-terpinene, γ-terpinene, α-phellandrene, myrcene, camphene, and ocimene; heptanal, octanal, decanal, benzaldehyde, salicylic aldehyde, phenylacetaldehyde, citronellal, hydroxycitronellal, hydrotropic aldehyde, ligustral, citral, α-hexyl cinnamic aldehyde, α Aldehydes such as amyl cinnamic aldehyde, lilial, cyclamen aldehyde, lyral, heliotropin, anisaldehyde, helional, vanillin, and ethyl vanillin; ethyl formate, methyl acetate, ethyl acetate, methyl propionate, methyl isobutyrate, ethyl isobutyrate, ethyl butyrate, propyl butyrate, isobutyl acetate, isobutyl isobutyrate, isobutyl butyrate, isobutyl isovalerate, ethyl-2-methylbutanol Acetate, Isoamyl Acetate, Terpinyl Acetate, Isoamyl Propionate, Amyl Propionate, Amyl Isobutyrate, Amyl Butyrate, Amyl Isovalerate, Allyl Hexanoate, Ethyl Acetoacetate, Ethyl Heptylate, Heptyl Acetate, Methyl Benzoate, Ethyl Benzoate, Ethyl Octylate, Styrallyl Acetate, Benzyl Acetate, Nonyl Acetate, Bornyl Acetate, Linalyl Acetate, Ortho-tert-Butylcyclohexyl esters and lactones such as methyl acetate, linalyl benzoate, benzyl benzoate, triethyl citrate, ethyl cinnamate, methyl salicylate, hexyl salicylate, hexyl acetate, hexyl butyrate, menthyl acetate, terpinyl acetate, anisyl acetate, phenylethyl isobutyrate, methyl jasmonate, methyl dihydrojasmonate, ethylene brassylate, γ-undecalactone, γ-nonyl lactone, cyclopentadecanolide, and coumarin;Ethers such as anisole, p-cresyl methyl ether, dimethylhydroquinone, methyl eugenol, β-naphthol methyl ether, β-naphthol ethyl ether, anethole, diphenyl oxide, rose oxide, galaxolide, and ambrox; isopropyl alcohol, cis-3-hexenol, heptanol, 2-octanol, dimetol, dihydromyrcenol, linalool, benzyl alcohol, citronellol, geraniol, nerol, terpineol, tetrahydrogeraniol, l-menthol, cedrol, santalol, thymol, anise alcohol, phenylethyl alcohol, and hexyl alcohol. Examples of fragrances include alcohols such as sanol, diacetyl, menthone, isomenthone, thiomenthone, acetophenone, α- or β-damascone, α- or β-damascenone, α-, β-, or γ-ionone, α-, β-, or γ-methylionone, methyl-β-naphthyl ketone, benzophenone, thiamin, acetylcedrene, α- or β-isomethylionone, α-, β-, or γ-irone, ketones such as maltol, ethyl maltol, cis-jasmone, dihydrojasmone, l-carvone, dihydrocarvone, and methyl amyl ketone, camphor, 1,8-cineole, allyl amyl glycolate, isopulegol, and allyl caproate. These fragrances can be used alone or in any combination of two or more to form a blended fragrance. Furthermore, the fragrance can also be used as a mixture (fragrance composition) containing fragrance ingredients, solvents, fragrance stabilizers, etc.

[0036] Examples of disinfecting ingredients include alcohols such as ethanol and isopropanol, imidazoles such as thiabendazole and methyl 2-benzimidazolylcarbamate, parabens such as butylparaben, ethylparaben, and methylparaben, benzoic acid, sodium benzoate, propionic acid, sodium propionate, triclosan, hinokitiol, isopropylmethylphenol, parachlorometaxylenol, 3-iodo-2-propynyl butylcarbamate (IPBC), benzalkonium chloride, and benzothonium chloride. , chlorhexidine gluconate, chlorhexidine hydrochloride, N-(dichlorofluoromethylthio)-phthalamide, N'-(dichlorofluoromethylthio)N,N'-dimethyl-N'-phenyl-sulfamide, polyoctylpolyaminoethylglycine, cetylpyridium chloride, 4,4-dimethyl-1,3-oxazolidine, poly(hexamethyl)biguanide hydrochloride, as well as natural oils such as origanum oil, cinnamon oil, lemongrass oil, peppermint oil, eucalyptus oil, moso bamboo extract, and grapefruit seed extract.

[0037] In the transpiration medicine of the present invention, various additives commonly used such as transpiration rate enhancers, fragrances, synergists, solvents, antioxidants, pigments, etc. can be added as desired, provided that the transpiration of the medicine (active ingredient) is not hindered. Examples of transpiration rate enhancers include phenethyl isothiocyanate and dimethyl himix acid.

[0038] In the present invention, a surfactant can be used, for example, one or more of alkyl sulfates, alkyl sulfonates, alkylaryl sulfonates, alkylaryl ethers, polyoxyethylenated alkylaryl ethers, polyethylene glycol ethers, polyhydric alcohol esters, and sugar alcohol derivatives.

[0039] In the present invention, the pest control component to be heated by the electric heating means is held in a carrier 5 and heated.

[0040] The carrier 5 that can be used in the present invention may be made of any of various commonly used materials, such as felt, cotton, pulp, nonwoven fabric, asbestos, ceramic, porcelain, earthenware, gypsum, bentonite, inorganic moldings, etc. Specific examples of the carrier 5 include porous porcelain, glass fiber, asbestos, and other inorganic fibers bound with a binder such as gypsum or bentonite; mineral powders such as kaolin, activated clay, talc, diatomaceous earth, clay, perlite, bentonite, alumina, silica, alumina-silica, titania, fired vitreous volcanic rock powder, and fired vitreous volcanic ash, either alone or in combination with wood flour, charcoal powder, activated carbon, or the like, and then heat-treated with a binder such as poval at about 150°C for several minutes; poval to which about 1 to 10% of a water-resistant agent such as melamine resin or ammonium dichromate has been added; and cross-linked starch, a mixture of cross-linked starch with α-starch, or a mixture of α-gluten and caprolactone, bound with a water-resistant binder. Synthetic resin-based binders can also be used.

[0041] Among these, preferred carriers 5 are diatomaceous earth or alumina ceramics, or materials obtained by kneading these with the aforementioned binders and then extruding them. The carrier 5 can be shaped, for example, in a plate, cylinder, rod, or honeycomb form. The pest control component can be retained on the carrier 5 by dripping the pest control component in its original form onto the carrier 5, or by infiltrating the carrier 5 with a solution of the pest control component dissolved in a solvent and then drying it. Alternatively, the pest control component can be mixed with an inorganic salt or organic binder and pressed into a tablet, or by adding water, kneading the mixture, extruding, and then drying the mixture. Examples of solvents that can be used include organic solvents, such as low-boiling solvents such as acetone, alcohol, and hexane; hydrocarbon solvents such as n-paraffin, isoparaffin, and liquid paraffin; medium-boiling solvents with a boiling point of 100 to 400°C, such as glycols and glycol ethers; and inorganic solvents such as phthalates, isopropyl myristate, and other fatty acid esters; surfactants; and water.

[0042] The content of the pest control component in the carrier 5 is 0.01 g / cm 3 ~10g / cm 3 is preferable, and more preferably 0.05 g / cm 3 ~5g / cm 3 In addition to the pest control component, additives that may be contained in the carrier 5 include the transpiration rate enhancers, efficacy enhancers, synergists, solvents, surfactants, antioxidants, and pigments, as described above.

[0043] The size of the bottom surface of the carrier 5 to be heated is preferably 0.1 cm 2 ~5cm 2 and more preferably 0.1 cm 2 ~3cm 2 and most preferably 0.1 cm 2 ~2cm 2 is.

[0044] The thickness of the carrier 5 is preferably 1 mm to 5 mm, more preferably 1 mm to 4 mm, and most preferably 1 mm to 3 mm.

[0045] <Evaluation test of the heating evaporation device> Through various tests, the present inventors have found that, as in the above-described embodiment, the surface temperature of the carrier 5 can be heated to a range of 200°C to 500°C within 5 to 60 seconds after the heating element 4 is energized, thereby enabling efficient evaporation of the drug. This will be explained below with reference to test examples.

[0046] (Test 1) In Test 1, the evaporation of the agent was confirmed while changing the time from application of electricity and the surface temperature of the carrier 5. In Test 1, a carrier 5 (diameter 7.2 mm, thickness 1 mm) prepared as described below was impregnated with 8 mg of metofluthrin as a pest control ingredient, and a sample was used which was placed in an aluminum cup (diameter (inner diameter) 8 mm, height 4 mm).

[0047] When the transpiration rate is low, the amount of drug that transpires decreases, so a transpiration rate of 40% was used as the benchmark for efficient drug transpirement.

[0048] As shown in Figure 2, the device used in Test 1 consisted of a copper wire attached to a heating element 4 (diameter 8 mm, resistance value at room temperature (before energization) 1.7 Ω), and the heating element 4 attached to a wooden base 23. A DC stabilized power supply 22 was connected to the end of the copper wire opposite to the end connected to the heating element 4. Note that the resistance value of the heating element 4 after energization did not change significantly from the value before energization, because heat was generated by resistance heating.

[0049] The method for producing the carrier 5 used in Test 1 will be described with reference to Table 1 below. First, powders weighed according to the weight values ​​shown in Table 1 are mixed. Then, this mixed powder is transferred to an iron bowl, and hot water at 70°C to 80°C is added. The powder to which the hot water has been added is kneaded and continues to be kneaded until it becomes a lump. Thereafter, it is formed into a rod with a diameter of 7.2 mm, dried overnight at 65°C, and then cut to a thickness of 1 mm to obtain the carrier 5. This completes the method for producing the carrier 5 used in Test 1.

[0050] [Table 1]

[0051] The test method will be explained with reference to Figures 2 and 3. The temperature in the test room was set to 27°C ± 2°C, a collection tube 10 filled with silica gel was connected to a vacuum pump 21, and a funnel 20 connected to the collection tube 10 was placed directly above the above-mentioned device (see Figure 2).

[0052] Then, the voltage of the DC stabilized power supply 22 was adjusted to a predetermined value, and evaporation tests were performed on the carrier 5 with heating for 10 seconds, 20 seconds, and 60 seconds so that all of the drug could be collected. In the evaporation tests, evaporation was started by turning on the DC stabilized power supply 22 and the vacuum pump 21. The evaporated drug was then collected in the collection tube 10, and after collection was completed, the collection tube 10 was detached from the vacuum pump 21 and the like.

[0053] Then, the silica gel used in the collection tube 10 was placed in a 450 ml glass bottle, and acetone was added until the silica gel was completely immersed in the glass bottle. The bottle was left overnight, and the drug captured by the silica gel was extracted. As a measurement method, only the acetone extract was taken out, concentrated, and analyzed using a gas chromatograph to measure the amount of Metofluthrin captured by the silica gel.

[0054] The test results will be explained with reference to Table 2 below and Figure 4. Table 2 shows the results of the evaporation test in Test 1. Figure 4 is a graph showing the relationship between "surface temperature" and "evaporation rate" in Table 2. In Table 2, "time" indicates the time elapsed since the current was turned on, "voltage" indicates the voltage applied to the heating element 4, and "surface temperature" indicates the surface temperature of the carrier 5. The evaporation rate in this test is calculated by "(amount of drug captured by silica gel / amount of drug initially supported) x 100".

[0055] The temperature was measured by using a thermometer of a temperature recorder (manufactured by GRAPHTEC) and bringing the thermometer into contact with the center of the carrier 5.

[0056] [Table 2]

[0057] Based on the relationship between surface temperature and evaporation rate shown in Figure 4 (i.e., the distribution of evaporation rate with respect to surface temperature), it can be confirmed that even with short heating times such as 10 or 60 seconds, as long as the upper limit is 500°C or less, an evaporation rate of 40% or more, which is the index mentioned above, can be achieved. Similarly, even with short heating times such as 10 or 60 seconds, as long as the lower limit is 200°C or more, an evaporation rate of 40% or more, which is the index mentioned above, can be achieved. Even when the heating time is set to 5 seconds, it can be estimated that the relationship between surface temperature and evaporation rate is the same as when the heating time is set to 10 or 60 seconds.

[0058] It should be noted that damage to the aluminum cup of the test device can be confirmed when the surface temperature exceeds 500° C. Therefore, it can be predicted that when the surface temperature exceeds 500° C., the thermal load on the housing 2 of this embodiment will be large.

[0059] (Test 2) In Test 2, it was confirmed whether the active ingredient (pest control ingredient) would transpire efficiently when the surface of the carrier 5 was instantaneously heated to 200°C or higher, even in carriers 5 other than the carrier 5 used in Test 1. In Test 2, a carrier (diameter 8 mm, thickness 1 mm) prepared as described below was impregnated with 8 mg of metofluthrin as the pest control ingredient, and a sample was placed in an aluminum cup (diameter 8 mm, height 4 mm).

[0060] The method for producing the carrier 5 used in Test 2 will be described with reference to Table 3 below. First, the powders weighed according to the weight values ​​shown in Table 3 are mixed. Then, this mixed powder is transferred to an iron bowl, and hot water at 70°C to 80°C is added. The powder to which the hot water has been added is kneaded and kneading continues until it becomes a lump. Thereafter, it is formed into a rod with a diameter of 8 mm, dried overnight at 65°C, and cut to a thickness of 1 mm to obtain the carrier 5. This completes the method for producing the carrier 5 used in Test 2.

[0061] [Table 3]

[0062] The apparatus used in Test 2 was the same as in Test 1. The test method was also the same as in Test 1.

[0063] When a test similar to Test 1 was conducted, in an evaporation test with heating for 10 seconds (voltage: 4.7 V), the surface temperature was 271°C and the evaporation rate was 69%. In addition, in an evaporation test with heating for 60 seconds (voltage: 3.4 V), the surface temperature was 375°C and the evaporation rate was 70%. Thus, in Test 2, as in Test 1, it was confirmed that an evaporation rate of 40% or more, which is the index, can be achieved by heating the surface of the carrier 5 to 200°C or more.

[0064] Therefore, from the results of Tests 1 and 2, it can be confirmed that even if the heating time is short, such as 5 to 60 seconds, by heating the surface temperature of the carrier 5 to 200°C or higher, the evaporation rate of 40% or more, which is the index, can be achieved without any limitations on the carrier 5.

[0065] (Test 3) In Test 3, it was confirmed whether the active ingredient (pest control ingredient) would transpire efficiently when the surface of the carrier 5 was instantaneously heated to 200°C or higher, even when a heating element 4 (diameter 8 mm, resistance value at room temperature (before power is applied) of 1.0Ω and 4.6Ω) with a different resistance value from the heating element 4 used in Test 2 (diameter 8 mm, resistance value at room temperature (before power is applied) of 1.7Ω) was used in Test 2, in a carrier 5 similar to that in Test 2.

[0066] The device used in Test 3 differs from Test 1 in that a mica plate was sandwiched between the heating element 4 and the carrier 5, but in other respects it was the same as Test 1 (see Figure 2). The mica plate was provided to take into consideration contamination of the heating element 4 and did not affect the test results. The test method was the same as Test 1. The test results will be explained with reference to Tables 4 and 5 below. Table 4 shows the results of the evaporation test when the resistance value of the heating element 4 was 1.0 Ω, and Table 5 shows the results of the evaporation test when the resistance value of the heating element 4 was 4.6 Ω.

[0067] [Table 4]

[0068] [Table 5]

[0069] As shown in Table 4, when measurements were performed with the heating element 4 having a resistance value of 1.0Ω and the heating time changed, it was confirmed that the surface temperature of the carrier 5 reached 200°C or higher and achieved the index evaporation rate of 40% or more for any heating time. Also, as shown in Table 5, when the heating element 4 had a resistance value of 4.6Ω (heating for 60 seconds), it was confirmed that the surface temperature reached 200°C or higher and achieved the index evaporation rate of 40% or more.

[0070] In other words, if the resistance value of the heating element 4 and the heating time of the support 5 are within a predetermined range, it can be confirmed that when the surface temperature of the support 5 reaches 200°C or higher, an evaporation rate of 40% or higher, which is the index, is achieved.

[0071] (Test 4) In Test 4, it was confirmed whether carriers 5 other than those used in Tests 1 and 2 could be heated to 200°C or higher within 5 to 60 seconds using a heating element with a resistance of 0.5 to 5 Ω. In Test 4, a sample was used in which a carrier (diameter 8 mm, thickness 1 mm) prepared as described below was impregnated with 8 mg of metofluthrin as a pest control ingredient.

[0072] The method for preparing the carrier 5 used in Test 4 will now be described. First, 170 ml of water was added to 200 g of calcined gypsum powder and mixed. The mixture of calcined gypsum powder and water was then thinly spread and formed into a 1 mm thick plate, which was then dried overnight at 65°C and punched out to an 8 mm diameter to prepare the carrier 5. This completes the method for preparing the carrier 5 used in Test 4.

[0073] The equipment used in Test 4 was the same as in Test 3. The test method was the same as in Test 1 (Test 3).

[0074] When a test similar to Test 1 (Test 3) was conducted, the surface temperature was 367°C in a 30-second heating evaporation test (voltage: 4.2 V). In other words, as in Tests 1 and 2, the surface temperature reached 200°C or higher, and it can be inferred that an evaporation rate of 40% or higher, which is the index, was achieved. As a result, it can be said that by heating the surface of the carrier 5 to 200°C or higher, an evaporation rate of 40% or higher, which is the index, can be achieved without being limited by the carrier 5.

[0075] (Test 5) In Test 5, an efficacy test against adult mosquitoes was conducted under conditions of a transpiration rate of approximately 40%, and the pest control efficacy was confirmed. In other words, a test was conducted to determine whether or not pest control efficacy was exhibited at an index transpiration rate of 40%. In Test 5, the carrier 5 (diameter 8 mm, thickness 1 mm) used in Test 2 was impregnated with 8 mg of metofluthrin as the pest control ingredient, and a sample was used that was placed in an aluminum cup (diameter 8 mm, height 4 mm).

[0076] The device used in Test 5 (hereinafter referred to as "thermal evaporation device 1a" for ease of explanation) consisted of a copper wire attached to a constant resistance heating element 4 (diameter 8 mm, resistance value before energization at room temperature 1.7 Ω), and the heating element 4 attached to a wooden base. A DC stabilized power supply 22 was connected to the end of the copper wire opposite to the end connected to the heating element 4. Note that the resistance value of the heating element 4 after energization was approximately the same as the value before energization, since heat was generated by resistance heating.

[0077] Figure 5 is a schematic diagram showing the evaluation test in Test 5. As shown in Figure 5, the thermal transpiration device 1a was placed in the center of a test room (12 tatami mats: 5.4 m × 3.6 m × 2.4 m height, temperature: 24.0°C, humidity: 72.0%). Two PET cages 30 (14-mesh, 23 cm × 23 cm PET netting folded in half to form a bag) containing test insects, female adult Culex pipiens pallens (approximately 20 individuals) 2 to 5 days after emergence, were placed diagonally at heights of 0.75 m (30B) and 1.5 m (30A) from the floor of the test room. Then, a DC stabilized power supply 22 (see Figure 2) was used to apply electricity (voltage 4.5 V) to the thermal transpiration device 1a for 60 seconds.

[0078] After the start of the application of electricity to the thermal evaporation device 1a (the evaporation rate of the drug was around 40%), the number of dead insects was observed over time. Observations were made every two minutes for two hours after the start of the application of electricity, and after two hours had passed, the test insects were moved by cage (30A, 30B) to a separate room (temperature: approximately 25°C), where they were given 1% sugar water, and the number of dead insects was observed 24 hours later.

[0079] The test results are set forth below with reference to Table 6, which shows efficacy results at an evaporation rate of approximately 40%.

[0080] [Table 6]

[0081] In the above-mentioned test, the efficacy test was conducted on adult mosquitoes in an unventilated test room. As a result, all mosquitoes were knocked down within 10 minutes, and the mortality rate after 24 hours was 100%. Therefore, the thermal evaporation device 1a can achieve a high pest control effect at an evaporation rate of approximately 40%.

[0082] Note that KT50 shown in Table 6 indicates the time required for 50% of all test insects to be knocked down. In other words, referring to Table 6, it can be confirmed that the time required for 50% of all test insects to be knocked down is less than 4 minutes. Similarly, KT90 shown in Table 6 indicates the time required for 90% of all test insects to be knocked down. In other words, referring to Table 6, it can be confirmed that the time required for 90% knockdown is less than 10 minutes.

[0083] (Test 6) In Test 6, the transpiration of active ingredients with different vapor pressures was confirmed. Specifically, in Test 6, it was confirmed whether fenothrin, which is less likely to transpire than metofluthrin, could be properly transpire. In addition, in Test 6, the same carrier 5 (diameter 7.2 mm, thickness 1 mm) used in Test 1 was impregnated with 8 mg of fenothrin as the pest control ingredient, and the sample was placed in an aluminum cup (diameter 8 mm, height 4 mm). Table 7 below shows the difference in vapor pressure between the metofluthrin used in Test 5 and the fenothrin used in this test.

[0084] [Table 7]

[0085] The apparatus used in Test 6 was the same as in Test 1. The test method was also the same as in Test 1.

[0086] The test results are described below with reference to Table 8. Table 8 shows the transpiration test results.

[0087] [Table 8]

[0088] Referring to Table 8, it can be seen that the transpiration rate is 40% or more even when fenothrin is used. Therefore, other pest control ingredients besides metofluthrin can also be used to properly transpire the active ingredients.

[0089] (Test 7) In Test 7, it was confirmed whether the active ingredient (sterilizing ingredient) of a drug (active ingredient: disinfecting ingredient) different from the drugs (active ingredient: pest control ingredient) used in Tests 1 to 6 would evaporate efficiently when the surface of carrier 5 was momentarily heated to 200°C or higher.

[0090] In Test 7, a sample was used in which an acetone solution in which isopropylmethylphenol as a disinfecting component was dissolved was dropped onto a carrier (diameter 8 mm, thickness 1 mm) prepared as described below, and 8 mg of isopropylmethylphenol was impregnated. Note that the carrier 5 used in Test 7 was the same as in Test 2.

[0091] The equipment used in Test 7 was the same as in Test 3. The test method was the same as in Test 1 (Test 3). The test results will be explained with reference to Table 9 below. Table 9 shows the transpiration test results.

[0092] [Table 9]

[0093] When a test similar to Test 1 was carried out, it was confirmed that the index transpiration rate of 40% or more was not achieved when the surface temperature of the carrier 5 was 200°C or lower, but the index transpiration rate of 40% or more was achieved when the surface temperature of the carrier 5 was 200°C or higher. In other words, it was confirmed that by heating the surface of the carrier 5 to 200°C or higher, the index transpiration rate of 40% or more was achieved, regardless of the drug contained in the carrier 5.

[0094] (Test 8) In Test 8, it was confirmed whether the active ingredient (fragrance ingredient) of a drug (active ingredient: fragrance ingredient) having an active ingredient different from the drug used in Tests 1 to 6 (active ingredient: pest control ingredient) and the drug used in Test 7 (active ingredient: disinfecting ingredient) could be efficiently evaporated when the surface of carrier 5 was momentarily heated to 200°C or higher.

[0095] In Test 8, a sample was used in which citronella oil as a fragrance ingredient was dropped onto a carrier (diameter 8 mm, thickness 1 mm) prepared as described below, and 20 mg of citronella oil was impregnated. Note that the carrier 5 used in Test 8 was the same as in Test 2.

[0096] The device used in Test 8 was the same as in Test 3. Regarding the test method, the device was placed in the center of a test room (6 tatami mats: 2.7 m × 3.6 m × 2.4 m height, temperature: 27°C, humidity: 60%, unventilated space), the DC stabilized power supply 22 (see FIG. 2) was adjusted to a predetermined value (voltage 2.0 V and 3.7 V), and electricity was applied to the device for 30 seconds. Two minutes after the end of electricity application, the scent intensity in the test room was subjected to a sensory evaluation.

[0097] The sensory evaluation was carried out by calculating the average of the evaluations of 10 people based on a 5-point scale (5: very strong scent, 4: scent, 3: slight scent, 2: almost no scent, 1: no scent at all). In Test 8, since the active ingredient was a fragrance ingredient, the test was evaluated by sensory evaluation, which can be carried out more efficiently than measuring the transpiration rate. The test results are explained with reference to Table 10 below. Table 10 shows the transpiration test results.

[0098] [Table 10]

[0099] When a test similar to Test 1 was carried out, it was confirmed that when the surface temperature of the carrier 5 was 200°C or lower, the drug (active ingredient; fragrance ingredient) was not sufficiently evaporated, but when the surface temperature of the carrier 5 was 200°C or higher, the drug was sufficiently evaporated. In other words, it was confirmed that by heating the surface of the carrier 5 to 200°C or higher, the drug contained in the carrier 5 was not limited, and the drug was sufficiently evaporated.

[0100] From Tests 1 to 8, it can be confirmed that regardless of the type of carrier 5 or the type of agent (including the type of pest control ingredient), even if the heating time is short, such as 5 to 60 seconds, heating the surface temperature of carrier 5 to within the range of 200°C to 500°C achieves an index transpiration rate of 40% or more. In other words, the heating transpiration device 1 of the present application has an excellent transpiration rate, and is sufficiently effective even when used for the purpose of pest control, for example.

[0101] For convenience, the thermal evaporation device 1 according to this embodiment (the device used in Tests 1 to 8) was tested using a DC stabilized power supply instead of a battery, but it was confirmed that similar results could be obtained with a battery.

[0102] <Other forms> The present invention is not limited to the above-described embodiments, and can be appropriately modified, improved, etc. Furthermore, the material, shape, size, number, location, etc. of each component in the above-described embodiments are arbitrary and not limited as long as they can achieve the present invention.

[0103] Here, the features of the embodiment of the thermal evaporation device 1 according to the present invention described above will be briefly summarized and listed below. [1] A thermal evaporation device (1) comprising: a carrier (5) containing a drug; a heating element (4) for heating the carrier (5); and a battery (3) for supplying power to the heating element (4), The heating element (4) is The battery (3) generates heat when power is supplied from the battery (3), The resistance value when the heat is stable is within the range of 0.7Ω to 5.0Ω. The heating and evaporation device (1) comprises: The heating element (4) is configured to heat the surface temperature of the carrier (5) to within a range of 200°C to 500°C within 5 to 60 seconds after the energization, thereby evaporating the drug. Heating evaporation device. [2] A chemical vaporization method using a heating vaporization device (1), The heating and evaporation device (1) The device comprises a carrier (5) containing a drug, a heating element (4) for heating the carrier, and a battery (3) for supplying power to the heating element (4), The heating element (4) is The battery (3) generates heat when power is supplied from the battery (3), The resistance value when the heat is stable is within the range of 0.7Ω to 5.0Ω. The drug evaporation method comprises: The method includes a step of heating the surface temperature of the carrier (5) to within a range of 200°C to 500°C within 5 to 60 seconds after the heating element (4) is energized, thereby evaporating the drug. Drug evaporation method. [Explanation of symbols]

[0104] 1. Heating evaporation device 2. Case 3 batteries 4 Heating elements 5. Carriers 6 Control Unit 10 Collection tube 20 Funnel 21 Vacuum pump 22 DC regulated power supply 23 Wooden Base 30A(30) Cage (height: 1.5m) 30B(30) Cage (height: 0.75m)

Claims

1. A heating and evaporation device comprising: a carrier containing a drug; a heating element for heating the carrier; and a battery for supplying power to the heating element, The heating element is The battery generates heat when power is supplied from the battery, The resistance value when the heat generation is stable is within the range of 0.7Ω to 5.0Ω, The heating and evaporation device comprises: The surface temperature of the carrier is heated to a range of 200°C to 500°C by heat radiation from the heating element within 5 to 60 seconds from the start of energization of the heating element, thereby evaporating the drug. Heating evaporation device.

2. A chemical vaporization method using a heating vaporization device, The heating and evaporation device is The device comprises a carrier containing a drug, a heating element for heating the carrier, and a battery for supplying power to the heating element, The heating element is The battery generates heat when power is supplied from the battery, The resistance value when the heat generation is stable is within the range of 0.7Ω to 5.0Ω, The drug evaporation method comprises: The method includes a step of heating the surface temperature of the carrier to a range of 200°C to 500°C by heat radiation from the heating element within 5 to 60 seconds from the start of current application to the heating element, thereby evaporating the drug. Drug evaporation method.

Images